AI Health Platform Secures $1.6M Seed Funding

A Canadian digital health innovator has successfully closed a $1.625 million seed funding round, signaling strong investor confidence in its AI-driven approach to complex reproductive health management. The capital infusion is earmarked for enhancing its sophisticated care coordination platform, designed to empower individuals navigating challenging health journeys.

Leading the investment was Graphite Ventures, joined by a robust syndicate including Conexus Venture Capital, Adrenaline Fund, and Phoenix Fire Fund, alongside a cohort of strategic angel investors. This collective backing underscores the significant market opportunity perceived in addressing unmet needs within the reproductive health sector, a field often characterized by lengthy diagnostic timelines and patient frustration.

The company, founded by Jessica Chalk, leverages a dual strategy of artificial intelligence and human oversight. Its platform functions as a comprehensive patient portal, enabling users to meticulously document their health history—from symptoms and test outcomes to appointments and personal observations. The AI component then analyzes this data to identify trends, generate actionable insights, and prepare patients for more productive clinical consultations. Crucially, trained healthcare professionals review and contextualize these AI-generated findings, ensuring accuracy and personalized support.

Initially focusing on fertility navigation, the platform is strategically expanding its scope to encompass the entire reproductive health spectrum. This includes conditions such as chronic pelvic pain, Polycystic Ovary Syndrome (PCOS), endometriosis, and perimenopause. The long-term vision extends to integrating support for cancer and autoimmune disease management, positioning the company as a holistic health companion.

“Reproductive health is marked by exceptionally high rates of patient dismissal and protracted diagnostic delays,” stated Jessica Chalk. “We are constructing the essential connective tissue—providing patients with structure, a reliable health memory, and expert guidance throughout their entire care continuum.” Aaron Bast of Graphite Ventures highlighted the platform's unique value proposition, noting it addresses “burden failure, not just an information gap,” in the intricate process of healthcare navigation.

The company's platform is currently accessible on both iOS and Android devices, offering complimentary AI-powered guidance and health record organization. Premium subscription tiers, starting at $19 per month, unlock access to personalized support from trained healthcare professionals. The newly acquired funds will be instrumental in accelerating product development, bolstering the clinical team, and driving user acquisition across North America. This strategic expansion aims to solidify the company's position in the rapidly evolving digital health market, where personalized and data-driven patient support is becoming increasingly critical.